Valar Labs Raises $22M Series A for Computational Histology AI Tests
Valar Labs was established with a vision to enhance cancer treatment precision.
Company Name: Valar Labs
Location: Palo Alto, CA
Sector: Healthcare, Biotechnology, Artificial Intelligence
Funding Details: Raised $22M in Series A funding. The round was led by DCVC and Andreessen Horowitz (a16z) Bio + Health, with participation from Pear VC.
Purpose of Investment: To expand operations and accelerate R&D efforts in computational histology AI tests.
Leadership: Co-led by Damir Vrabac (COO), Anirudh Joshi (CEO), and Viswesh Krishna (CTO).
Board Additions: Vineeta Agarwala, MD, PhD, from a16z Bio + Health, and James Hardiman from DCVC will be joining the company's Board of Directors as part of this funding round.
Product: Valar Labs is dedicated to advancing precision medicine through its proprietary computational histology AI (CHAI) tests. These tests are designed to predict patient responses to cancer therapies, enabling personalized treatment strategies. The company’s flagship product, the Vesta bladder cancer test, provides insights into patient prognosis by predicting responses to BCG therapy and offering risk stratification for recurrence and progression.
About Company: Established with a vision to enhance cancer treatment precision, Valar Labs operates out of a CLIA-certified laboratory in Houston, Texas. Its services are accessible to physicians nationwide through an online platform.
